Are your beauty favourites quietly shrinking – while prices stay the same? From shampoo bottles downsizing to lipsticks ...

PRGO beats Q3 earnings estimates but misses on sales. It also trims the 2025 outlook and launches a strategic review of its infant formula unit.

Once a company with presence in various industries, including generic pharmaceuticals and animal health, Perrigo spent the last few years divesting noncore businesses to simplify its operation and ...

Amazon is testing a robot-powered "store within a store" at a Whole Foods Market near Philadelphia, merging the grocer's ...

A man in Florida was arrested on a DUI charge after failing a sobriety test — while dressed up as a prison inmate for a ...

In a now-viral TikTok with more than 279,000 views, Haley — who goes by @granolablossom — explains that while her family was ...

The current quarter introduced a downward revision to net sales and EPS guidance, with the new EPS range of $2.70 to $2.80 replacing the previous $2.90 to $3.10 target. Management now projects organic ...

Q3 2025 Earnings Call November 5, 2025 8:30 AM ESTCompany ParticipantsBradley Joseph - Vice President of Global ...

Perrigo said on Wednesday it has initiated a strategic review of its infant formula business as the consumer health company shifts its focus to higher-margin branded products.

Despite the earnings beat, Perrigo lowered its full-year 2025 outlook, now expecting adjusted earnings of $2.70 to $2.80 per share, below the previous analyst consensus of $2.98. The company also ...

Perrigo is initiating a review of its infant formula business, citing an external environment that has made the segment's fit with the company's over-the-counter businesses less strategic, the company ...

Third Quarter 2025 YoY Highlights: Net Sales: $1.04 billion, down 4.1% year-over-year as favorable currency translation (+1.6 ...